Official reprint from UpToDate®
www.uptodate.com ©2015 UpToDate®

Placement and management of indwelling ureteral stents

Stephen Nakada, MD
Sutchin Patel, MD
Section Editor
Jerome P Richie, MD, FACS
Deputy Editor
Wenliang Chen, MD, PhD


Ureteral stents are one of the most common devices used by urologists. They are placed with cystoscopic guidance in an operating room setting. Ureteral stents are used to relieve ureteral obstruction, promote ureteral healing following surgery, and to assist with ureteral identification during pelvic surgery. Ureteral stent placement is associated with some degree of morbidity in the majority of patients that ranges from generalized urinary discomfort to urinary tract infection or obstruction. Much of the morbidity is related to the biocompatibility of the materials used to fashion the stent and, to some extent, their design; unfortunately, the ideal stent has yet to be discovered.

This topic will discuss the indications for ureteral stenting, technique of ureteral stent placement, management of stents, and stent complications. The management of urinary obstruction and urinary tract infection are discussed in detail elsewhere. (See "Clinical manifestations and diagnosis of urinary tract obstruction and hydronephrosis" and "Sampling and evaluation of voided urine in the diagnosis of urinary tract infection in adults".)


Ureteral stents are functionally used to re-establish or maintain the patency of the ureter. Ureteral stents passively dilate the ureter; urine flows through the center of the hollow stent as well as around the stent, facilitating the passage of debris [1,2]. Stent insertion initially increases ureteral peristaltic activity, but with time, the frequency and amplitude of ureteral peristalsis decreases [3-5]. Indications for ureteral stent placement include the following:

Ureteral obstruction — Ureteral obstruction due to nephrolithiasis, tumor, or retroperitoneal fibrosis can be uncomplicated, or complicated by urinary tract infection, renal insufficiency, or renal failure [6]. Patients with complicated obstruction need prompt decompression of the urinary tract with either placement of an indwelling ureteral stent or a percutaneous nephrostomy tube [7-9]. Retrograde ureteral stent placement and percutaneous nephrostomy both effectively relieve obstruction and infection due to ureteral calculi. In two randomized trials comparing both treatment modalities, neither modality demonstrated superiority in promoting a more rapid recovery after drainage [10,11]. The management of urinary tract obstruction is discussed in detail elsewhere. (See "Clinical manifestations and diagnosis of urinary tract obstruction and hydronephrosis" and "Management of ureteral calculi".)

A ureteral stent is generally chosen first to help relieve urinary tract obstruction because it is less invasive and has a lower risk of bleeding compared with placement of a percutaneous nephrostomy tube. However, in cases where a stent cannot be placed endoscopically or if the patient will require future percutaneous treatment of their stone burden, a percutaneous nephrostomy tube is placed primarily.


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Oct 2015. | This topic last updated: Apr 30, 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2015 UpToDate, Inc.
  1. Siggers JH, Waters S, Wattis J, Cummings L. Flow dynamics in a stented ureter. Math Med Biol 2009; 26:1.
  2. Ramsay JW, Payne SR, Gosling PT, et al. The effects of double J stenting on unobstructed ureters. An experimental and clinical study. Br J Urol 1985; 57:630.
  3. Venkatesh R, Landman J, Minor SD, et al. Impact of a double-pigtail stent on ureteral peristalsis in the porcine model: initial studies using a novel implantable magnetic sensor. J Endourol 2005; 19:170.
  4. Lennon GM, Thornhill JA, Grainger R, et al. Double pigtail ureteric stent versus percutaneous nephrostomy: effects on stone transit and ureteric motility. Eur Urol 1997; 31:24.
  5. Waterman, BJ, Jerde, T, Nakada, SY. Ureteral physiology: implications in urological practice. AUA Update Series 2006; Vol 25, Lesson 17.
  6. Fiuk J, Bao Y, Calleary JG, et al. The use of internal stents in chronic ureteral obstruction. J Urol 2015; 193:1092.
  7. Sountoulides P, Pardalidis N, Sofikitis N. Endourologic management of malignant ureteral obstruction: indications, results, and quality-of-life issues. J Endourol 2010; 24:129.
  8. Borofsky MS, Walter D, Shah O, et al. Surgical decompression is associated with decreased mortality in patients with sepsis and ureteral calculi. J Urol 2013; 189:946.
  9. Izumi K, Mizokami A, Maeda Y, et al. Current outcome of patients with ureteral stents for the management of malignant ureteral obstruction. J Urol 2011; 185:556.
  10. Pearle MS, Pierce HL, Miller GL, et al. Optimal method of urgent decompression of the collecting system for obstruction and infection due to ureteral calculi. J Urol 1998; 160:1260.
  11. Ramsey S, Robertson A, Ablett MJ, et al. Evidence-based drainage of infected hydronephrosis secondary to ureteric calculi. J Endourol 2010; 24:185.
  12. Shen P, Jiang M, Yang J, et al. Use of ureteral stent in extracorporeal shock wave lithotripsy for upper urinary calculi: a systematic review and meta-analysis. J Urol 2011; 186:1328.
  13. Ramasamy R, Afaneh C, Katz M, et al. Comparison of complications of laparoscopic versus laparoendoscopic single site donor nephrectomy using the modified Clavien grading system. J Urol 2011; 186:1386.
  14. Haleblian G, Kijvikai K, de la Rosette J, Preminger G. Ureteral stenting and urinary stone management: a systematic review. J Urol 2008; 179:424.
  15. Denstedt JD, Wollin TA, Sofer M, et al. A prospective randomized controlled trial comparing nonstented versus stented ureteroscopic lithotripsy. J Urol 2001; 165:1419.
  16. Wignall, GR, Denstedt, JD. Ureteral stents. AUA Update Series 2008; Lesson 12, Volume 27, pp102.
  17. Preminger GM, Tiselius HG, Assimos DG, et al. 2007 guideline for the management of ureteral calculi. J Urol 2007; 178:2418.
  18. Chandhoke PS, Barqawi AZ, Wernecke C, Chee-Awai RA. A randomized outcomes trial of ureteral stents for extracorporeal shock wave lithotripsy of solitary kidney or proximal ureteral stones. J Urol 2002; 167:1981.
  19. Pengfei S, Yutao L, Jie Y, et al. The results of ureteral stenting after ureteroscopic lithotripsy for ureteral calculi: a systematic review and meta-analysis. J Urol 2011; 186:1904.
  20. Anderson, KJ, Kabalin, JN, Cadeddu, JA. Surgical anatomy of the retroperitoneum, adrenals, kidneys and ureters. In: Campbell-Walsh Urology, 1, Wein (Ed), 2007..
  21. Brooks, JD. Anatomy of the lower urinary tract and male genitalia. In: Campbell-Walsh Urology, 1, Wein (Ed), 2007..
  22. Schlussel, RN, Retik, AB. Ectopic ureter, ureterocele, and other anomalies of the ureter. In: Campbell-Walsh Urology, 4, Wein (Ed), 2007..
  23. Duvdevani M, Chew BH, Denstedt JD. Minimizing symptoms in patients with ureteric stents. Curr Opin Urol 2006; 16:77.
  24. Bockholt NA, Wild TT, Gupta A, Tracy CR. Ureteric stent placement with extraction string: no strings attached? BJU Int 2012; 110:E1069.
  25. Zimskind PD, Fetter TR, Wilkerson JL. Clinical use of long-term indwelling silicone rubber ureteral splints inserted cystoscopically. J Urol 1967; 97:840.
  26. Marx M, Bettmann MA, Bridge S, et al. The effects of various indwelling ureteral catheter materials on the normal canine ureter. J Urol 1988; 139:180.
  27. Chew BH, Denstedt JD. Technology insight: Novel ureteral stent materials and designs. Nat Clin Pract Urol 2004; 1:44.
  28. Denstedt JD, Wollin TA, Reid G. Biomaterials used in urology: current issues of biocompatibility, infection, and encrustation. J Endourol 1998; 12:493.
  29. Lingeman JE, Schulsinger DA, Kuo RL. Phase I trial of a temporary ureteral drainage stent. J Endourol 2003; 17:169.
  30. Hadaschik BA, Paterson RF, Fazli L, et al. Investigation of a novel degradable ureteral stent in a porcine model. J Urol 2008; 180:1161.
  31. Chew BH, Paterson RF, Clinkscales KW, et al. In vivo evaluation of the third generation biodegradable stent: a novel approach to avoiding the forgotten stent syndrome. J Urol 2013; 189:719.
  32. Liatsikos EN, Karnabatidis D, Katsanos K, et al. Ureteral metal stents: 10-year experience with malignant ureteral obstruction treatment. J Urol 2009; 182:2613.
  33. Novara G, Ficarra V, D'Elia C, et al. Prospective evaluation with standardised criteria for postoperative complications after robotic-assisted laparoscopic radical prostatectomy. Eur Urol 2010; 57:363.
  34. Ilie CP, Mischianu D. Editorial comment on: Ureteral obstruction: is the full metallic double-pigtail stent the way to go? Eur Urol 2010; 57:486.
  35. Meria P. Editorial comment on: Ureteral obstruction: is the full metallic double-pigtail stent the way to go? Eur Urol 2010; 57:487.
  36. Hendlin K, Korman E, Monga M. New metallic ureteral stents: improved tensile strength and resistance to extrinsic compression. J Endourol 2012; 26:271.
  37. Benson AD, Taylor ER, Schwartz BF. Metal ureteral stent for benign and malignant ureteral obstruction. J Urol 2011; 185:2217.
  38. Goldsmith ZG, Wang AJ, Bañez LL, et al. Outcomes of metallic stents for malignant ureteral obstruction. J Urol 2012; 188:851.
  39. Calleary JG. Chronic indwelling ureteral stents--what is the optimal approach? J Urol 2011; 185:2016.
  40. Modi AP, Ritch CR, Arend D, et al. Multicenter experience with metallic ureteral stents for malignant and chronic benign ureteral obstruction. J Endourol 2010; 24:1189.
  41. Sountoulides P, Kaplan A, Kaufmann OG, Sofikitis N. Current status of metal stents for managing malignant ureteric obstruction. BJU Int 2010; 105:1066.
  42. Pollak JS, Rosenblatt MM, Egglin TK, et al. Treatment of ureteral obstructions with the Wallstent endoprosthesis: preliminary results. J Vasc Interv Radiol 1995; 6:417.
  43. Lang EK, Irwin RJ, Lopez-Martinez RA, et al. Placement of metallic stents in ureters obstructed by carcinoma of the cervix to maintain renal function in patients undergoing long-term chemotherapy. AJR Am J Roentgenol 1998; 171:1595.
  44. Kadlec AO, Ellimoottil CS, Greco KA, Turk TM. Five-year experience with metallic stents for chronic ureteral obstruction. J Urol 2013; 190:937.
  45. Chen HC, Shen SH, Wang JH, et al. Parallel second stent placement for refractory ureteral stent malfunction in malignant ureteral obstruction. J Vasc Interv Radiol 2011; 22:1012.
  46. Beiko DT, Knudsen BE, Denstedt JD. Advances in ureteral stent design. J Endourol 2003; 17:195.
  47. Riedl CR, Witkowski M, Plas E, Pflueger H. Heparin coating reduces encrustation of ureteral stents: a preliminary report. Int J Antimicrob Agents 2002; 19:507.
  48. Tenke P, Riedl CR, Jones GL, et al. Bacterial biofilm formation on urologic devices and heparin coating as preventive strategy. Int J Antimicrob Agents 2004; 23 Suppl 1:S67.
  49. Chew BH, Duvdevani M, Denstedt JD. New developments in ureteral stent design, materials and coatings. Expert Rev Med Devices 2006; 3:395.
  50. Stickler DJ. Biomaterials to prevent nosocomial infections: is silver the gold standard? Curr Opin Infect Dis 2000; 13:389.
  51. Park HK, Paick SH, Kim HG, et al. The impact of ureteral stent type on patient symptoms as determined by the ureteral stent symptom questionnaire: a prospective, randomized, controlled study. J Endourol 2015; 29:367.
  52. Lingeman JE, Preminger GM, Goldfischer ER, et al. Assessing the impact of ureteral stent design on patient comfort. J Urol 2009; 181:2581.
  53. Pilcher JM, Patel U. Choosing the correct length of ureteric stent: a formula based on the patient's height compared with direct ureteric measurement. Clin Radiol 2002; 57:59.
  54. Mardis HK, Kroeger RM, Morton JJ, Donovan JM. Comparative evaluation of materials used for internal ureteral stents. J Endourol 1993; 7:105.
  55. Stoller ML, Schwartz BF, Frigstad JR, et al. An in vitro assessment of the flow characteristics of spiral-ridged and smooth-walled JJ ureteric stents. BJU Int 2000; 85:628.
  56. Gerber R, Nitz C, Studer UE, Danuser H. Spiral stent versus standard stent in patients with midsize renal stones treated with extracorporeal shock wave lithotripsy: which stent works better? A prospective randomized trial. J Urol 2004; 172:965.
  57. Liu JS, Hrebinko RL. The use of 2 ipsilateral ureteral stents for relief of ureteral obstruction from extrinsic compression. J Urol 1998; 159:179.
  58. Hafron J, Ost MC, Tan BJ, et al. Novel dual-lumen ureteral stents provide better ureteral flow than single ureteral stent in ex vivo porcine kidney model of extrinsic ureteral obstruction. Urology 2006; 68:911.
  59. Davenport K, Kumar V, Collins J, et al. New ureteral stent design does not improve patient quality of life: a randomized, controlled trial. J Urol 2011; 185:175.
  60. Cadieux PA, Chew BH, Knudsen BE, et al. Triclosan loaded ureteral stents decrease proteus mirabilis 296 infection in a rabbit urinary tract infection model. J Urol 2006; 175:2331.
  61. Krambeck AE, Walsh RS, Denstedt JD, et al. A novel drug eluting ureteral stent: a prospective, randomized, multicenter clinical trial to evaluate the safety and effectiveness of a ketorolac loaded ureteral stent. J Urol 2010; 183:1037.
  62. Barnes KT, Bing MT, Tracy CR. Do ureteric stent extraction strings affect stent-related quality of life or complications after ureteroscopy for urolithiasis: a prospective randomised control trial. BJU Int 2014; 113:605.
  63. Jones JS. Shortened pull-string simplifies office-based ureteral stent removal. Urology 2002; 60:1095.
  64. Wolf JS Jr, Bennett CJ, Dmochowski RR, et al. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol 2008; 179:1379.
  65. Wolf, JS, Bennett, CJ, Dmochowski, RR et al. The best practice policy statement of urologic surgery antimicrobial prophylaxis. American Urological Association, 2008. auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/antimicroprop08.pdf (Accessed on February 11, 2010).
  66. Christiano AP, Hollowell CM, Kim H, et al. Double-blind randomized comparison of single-dose ciprofloxacin versus intravenous cefazolin in patients undergoing outpatient endourologic surgery. Urology 2000; 55:182.
  67. Sivalingam S, Tamm-Daniels I, Nakada SY. Office-based ureteral stent placement under local anesthesia for obstructing stones is safe and efficacious. Urology 2013; 81:498.
  68. Gershman B, Eisner BH, Sheth S, Sacco DE. Ureteral stenting and retrograde pyelography in the office: clinical outcomes, cost effectiveness, and time savings. J Endourol 2013; 27:662.
  69. Theckumparampil N, Elsamra SE, Carons A, et al. Symptoms after removal of ureteral stents. J Endourol 2015; 29:246.
  70. Loh-Doyle JC, Low RK, Monga M, Nguyen MM. Patient experiences and preferences with ureteral stent removal. J Endourol 2015; 29:35.
  71. Tadros NN, Bland L, Legg E, et al. A single dose of a non-steroidal anti-inflammatory drug (NSAID) prevents severe pain after ureteric stent removal: a prospective, randomised, double-blind, placebo-controlled trial. BJU Int 2013; 111:101.
  72. Sameh WM, Eid AA. Pressure transmission through ureteric stents: a novel in vivo human study. Urology 2012; 79:766.
  73. Erturk E, Sessions A, Joseph JV. Impact of ureteral stent diameter on symptoms and tolerability. J Endourol 2003; 17:59.
  74. Joshi HB, Stainthorpe A, MacDonagh RP, et al. Indwelling ureteral stents: evaluation of symptoms, quality of life and utility. J Urol 2003; 169:1065.
  75. Joshi HB, Okeke A, Newns N, et al. Characterization of urinary symptoms in patients with ureteral stents. Urology 2002; 59:511.
  76. Joshi HB, Newns N, Stainthorpe A, et al. Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure. J Urol 2003; 169:1060.
  77. Giannarini G, Keeley FX Jr, Valent F, et al. Predictors of morbidity in patients with indwelling ureteric stents: results of a prospective study using the validated Ureteric Stent Symptoms Questionnaire. BJU Int 2011; 107:648.
  78. Park SC, Jung SW, Lee JW, Rim JS. The effects of tolterodine extended release and alfuzosin for the treatment of double-j stent-related symptoms. J Endourol 2009; 23:1913.
  79. Yakoubi R, Lemdani M, Monga M, et al. Is there a role for α-blockers in ureteral stent related symptoms? A systematic review and meta-analysis. J Urol 2011; 186:928.
  80. Lee SJ, Yoo C, Oh CY, et al. Stent Position Is More Important than α-Blockers or Anticholinergics for Stent-Related Lower Urinary Tract Symptoms after Ureteroscopic Ureterolithotomy: A Prospective Randomized Study. Korean J Urol 2010; 51:636.
  81. Norris RD, Sur RL, Springhart WP, et al. A prospective, randomized, double-blinded placebo-controlled comparison of extended release oxybutynin versus phenazopyridine for the management of postoperative ureteral stent discomfort. Urology 2008; 71:792.
  82. Beiko DT, Watterson JD, Knudsen BE, et al. Double-blind randomized controlled trial assessing the safety and efficacy of intravesical agents for ureteral stent symptoms after extracorporeal shockwave lithotripsy. J Endourol 2004; 18:723.
  83. Wang CJ, Huang SW, Chang CH. Effects of specific alpha-1A/1D blocker on lower urinary tract symptoms due to double-J stent: a prospectively randomized study. Urol Res 2009; 37:147.
  84. Deliveliotis C, Chrisofos M, Gougousis E, et al. Is there a role for alpha1-blockers in treating double-J stent-related symptoms? Urology 2006; 67:35.
  85. Beddingfield R, Pedro RN, Hinck B, et al. Alfuzosin to relieve ureteral stent discomfort: a prospective, randomized, placebo controlled study. J Urol 2009; 181:170.
  86. Damiano R, Autorino R, De Sio M, et al. Effect of tamsulosin in preventing ureteral stent-related morbidity: a prospective study. J Endourol 2008; 22:651.
  87. Wang CJ, Huang SW, Chang CH. Effects of tamsulosin on lower urinary tract symptoms due to double-J stent: a prospective study. Urol Int 2009; 83:66.
  88. Nazim SM, Ather MH. Alpha-blockers impact stent-related symptoms: a randomized, double-blind, placebo-controlled trial. J Endourol 2012; 26:1237.
  89. Mokhtari G, Shakiba M, Ghodsi S, et al. Effect of terazosin on lower urinary tract symptoms and pain due to double-J stent: a double-blind placebo-controlled randomized clinical trial. Urol Int 2011; 87:19.
  90. Falahatkar S, Hemmati H, Gholamjani Moghaddam K. Intracaval migration: an uncommon complication of ureteral Double-J stent placement. J Endourol 2012; 26:119.
  91. Bieniek JM, Meade PG. Reflux anuria after prophylactic ureteral catheter removal: a case description and review of the literature. J Endourol 2012; 26:294.
  92. van den Bergh RC, Moll FL, de Vries JP, et al. Arterio-ureteral fistula: 11 new cases of a wolf in sheep's clothing. J Urol 2008; 179:578.
  93. Paick SH, Park HK, Oh SJ, Kim HH. Characteristics of bacterial colonization and urinary tract infection after indwelling of double-J ureteral stent. Urology 2003; 62:214.
  94. Kehinde EO, Rotimi VO, Al-Hunayan A, et al. Bacteriology of urinary tract infection associated with indwelling J ureteral stents. J Endourol 2004; 18:891.
  95. Kehinde EO, Rotimi VO, Al-Awadi KA, et al. Factors predisposing to urinary tract infection after J ureteral stent insertion. J Urol 2002; 167:1334.
  96. Akay AF, Aflay U, Gedik A, et al. Risk factors for lower urinary tract infection and bacterial stent colonization in patients with a double J ureteral stent. Int Urol Nephrol 2007; 39:95.
  97. Breau RH, Norman RW. Optimal prevention and management of proximal ureteral stent migration and remigration. J Urol 2001; 166:890.
  98. Slaton JW, Kropp KA. Proximal ureteral stent migration: an avoidable complication? J Urol 1996; 155:58.
  99. Kawahara T, Ito H, Terao H, et al. Ureteral stent encrustation, incrustation, and coloring: morbidity related to indwelling times. J Endourol 2012; 26:178.
  100. Tunney MM, Keane PF, Jones DS, Gorman SP. Comparative assessment of ureteral stent biomaterial encrustation. Biomaterials 1996; 17:1541.
  101. Robert M, Boularan AM, El Sandid M, Grasset D. Double-J ureteric stent encrustations: clinical study on crystal formation on polyurethane stents. Urol Int 1997; 58:100.
  102. Joshi H. Re: Ureteral stent encrustation, incrustation, and coloring: morbidity related to indwelling times. J Endourol 2012; 26:924.
  103. Ringel A, Richter S, Shalev M, Nissenkorn I. Late complications of ureteral stents. Eur Urol 2000; 38:41.
  104. Singh I, Gupta NP, Hemal AK, et al. Severely encrusted polyurethane ureteral stents: management and analysis of potential risk factors. Urology 2001; 58:526.
  105. Lam JS, Gupta M. Tips and tricks for the management of retained ureteral stents. J Endourol 2002; 16:733.
  106. Miyaoka R, Hendlin K, Monga M. Resistance to extrinsic compression and maintenance of intraluminal flow in coil-reinforced stents (Silhouette Scaffold Device): an in vitro study. J Endourol 2010; 24:595.
  107. Cass AS, Kavaney P, Levine L, et al. Extracorporeal shock wave lithotripsy for calcified ureteral stent. J Endourol 1993; 7:7.
  108. Bultitude MF, Tiptaft RC, Glass JM, Dasgupta P. Management of encrusted ureteral stents impacted in upper tract. Urology 2003; 62:622.
  109. Vanderbrink BA, Rastinehad AR, Ost MC, Smith AD. Encrusted urinary stents: evaluation and endourologic management. J Endourol 2008; 22:905.
  110. Withington J, Wong K, Bultitude M, O'Brien T. The forgotten ureteric stent: what next? BJU Int 2014; 113:850.
  111. Lynch MF, Ghani KR, Frost I, Anson KM. Preventing the forgotten ureteral stent: implementation of a web-based stent registry with automatic recall application. Urology 2007; 70:423.
  112. Ather MH, Talati J, Biyabani R. Physician responsibility for removal of implants: the case for a computerized program for tracking overdue double-J stents. Tech Urol 2000; 6:189.
  113. Jarrard DJ, Gerber GS, Lyon ES. Management of acute ureteral obstruction in pregnancy utilizing ultrasound-guided placement of ureteral stents. Urology 1993; 42:263.
  114. Borboroglu PG, Kane CJ. Current management of severely encrusted ureteral stents with a large associated stone burden. J Urol 2000; 164:648.
  115. Goldfarb RA, Neerhut GJ, Lederer E. Management of acute hydronephrosis of pregnancy by ureteral stenting: risk of stone formation. J Urol 1989; 141:921.
  116. Evans HJ, Wollin TA. The management of urinary calculi in pregnancy. Curr Opin Urol 2001; 11:379.